362 filings
Page 13 of 19
10-Q
2019 Q1
PHASQ
PhaseBio Pharmaceuticals Inc
Quarterly report
9 May 19
4:11pm
8-K
PHASQ
PhaseBio Pharmaceuticals Inc
9 May 19
PhaseBio Reports First Quarter 2019 Financial and Business Results
4:05pm
SC 13G
Rock Springs Capital Management LP
22 Apr 19
PhaseBio Pharmaceuticals Inc
1:41pm
424B4
PHASQ
PhaseBio Pharmaceuticals Inc
12 Apr 19
Prospectus supplement with pricing info
4:32pm
S-1MEF
PHASQ
PhaseBio Pharmaceuticals Inc
11 Apr 19
Registration of additional securities for an S-1
9:09pm
EFFECT
PHASQ
PhaseBio Pharmaceuticals Inc
11 Apr 19
Notice of effectiveness
12:00am
8-K
PHASQ
PhaseBio Pharmaceuticals Inc
10 Apr 19
Regulation FD Disclosure
8:00am
CORRESP
PHASQ
PhaseBio Pharmaceuticals Inc
10 Apr 19
Correspondence with SEC
12:00am
CORRESP
PHASQ
PhaseBio Pharmaceuticals Inc
10 Apr 19
Correspondence with SEC
12:00am
S-1
PHASQ
PhaseBio Pharmaceuticals Inc
IPO registration
9 Apr 19
4:03pm
8-K
PHASQ
PhaseBio Pharmaceuticals Inc
9 Apr 19
PhaseBio Announces Global License of PB1023 for the Treatment of Sarcopenia-Related Diseases to ImmunoForge
8:01am
CORRESP
PHASQ
PhaseBio Pharmaceuticals Inc
9 Apr 19
Correspondence with SEC
12:00am
CORRESP
PHASQ
PhaseBio Pharmaceuticals Inc
9 Apr 19
Correspondence with SEC
12:00am
8-K
PHASQ
PhaseBio Pharmaceuticals Inc
8 Apr 19
PhaseBio Receives FDA Breakthrough Therapy Designation for PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor
4:25pm
UPLOAD
PHASQ
PhaseBio Pharmaceuticals Inc
8 Apr 19
Letter from SEC
12:00am
DEF 14A
PHASQ
PhaseBio Pharmaceuticals Inc
5 Apr 19
Definitive proxy
4:05pm
8-K
PHASQ
PhaseBio Pharmaceuticals Inc
4 Apr 19
Entry into a Material Definitive Agreement
4:05pm
DRS
PHASQ
PhaseBio Pharmaceuticals Inc
29 Mar 19
Draft registration statement
12:00am
10-K
2018 FY
PHASQ
PhaseBio Pharmaceuticals Inc
26 Mar 19
Annual report
4:45pm
S-8
PHASQ
PhaseBio Pharmaceuticals Inc
26 Mar 19
Registration of securities for employees
4:10pm